The first asymmetric synthesis of a very promising antituberculosis drug candidate, R207910, was achieved by developing two novel catalytic transformations; a catalytic enantioselective proton migration and a catalytic diastereoselective allylation of an intermediate α-chiral ketone. Using 2.5 mol% of a Y-catalyst derived from Y (HMDS) 3 and the new chiral ligand 9, 1.25 mol% of p-methoxypyridine N-oxide (MEPO), and 0.5 mol% ...
